Journal Updates

March-2014

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with Chronic Hepatitis C
Management of Neonatal Cholestasis: Consensus Statement of the Pediatric Gastroenterology Chapter of Indian Academy of...
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients
On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B...
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma...
The contribution of viral hepatitis to the burden of chronic liver disease in the United States

February-2014

Effect of molecular adsorbents recirculating system treatment in children with acute liver failure caused by Wilson disease.
Factors that predict mortality in children with Wilson disease associated acute liver failure and comparison of Wilson...
Chronic hepatitis E: a review of the literature.
Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver...
Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune...
Acute Liver Failure Study Group. Steroid use in acute liver failure

January-2014

Treatment of patients with dual hepatitis C virus and hepatitis Bvirus infection: Resolved and unresolved issues
Prevention and risk factors of Hepatitis B recurrence after living donor liver transplantation
Challenge of meeting fellowship procedural guidelines in therapeutic endoscopy and liver biopsy.
Improved outcomes in liver transplantation in children with acute liver failure
Hepatitis A in children- clinical course, complications and laboratory profile

December-2013

Ultrasonographic predictors of esophageal varices
Perinatal transmission of Hepatitis C virus

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: